These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 14607306

  • 1. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
    Wong KS, Lu CS, Shan DE, Yang CC, Tsoi TH, Mok V.
    J Neurol Sci; 2003 Dec 15; 216(1):81-7. PubMed ID: 14607306
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul 09; 278(2):125-30. PubMed ID: 9214527
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
    Pinter MM, Pogarell O, Oertel WH.
    J Neurol Neurosurg Psychiatry; 1999 Apr 09; 66(4):436-41. PubMed ID: 10201413
    [Abstract] [Full Text] [Related]

  • 4. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group.
    JAMA; 2000 Oct 18; 284(15):1931-8. PubMed ID: 11035889
    [Abstract] [Full Text] [Related]

  • 5. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M, Markham A.
    Drugs Aging; 1998 Jun 18; 12(6):495-514. PubMed ID: 9638397
    [Abstract] [Full Text] [Related]

  • 6. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul 18; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 7. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
    Guttman M.
    Neurology; 1997 Oct 18; 49(4):1060-5. PubMed ID: 9339690
    [Abstract] [Full Text] [Related]

  • 8. Pramipexole in patients with early Parkinson's disease.
    Hubble JP, Koller WC, Cutler NR, Sramek JJ, Friedman J, Goetz C, Ranhosky A, Korts D, Elvin A.
    Clin Neuropharmacol; 1995 Aug 18; 18(4):338-47. PubMed ID: 8665547
    [Abstract] [Full Text] [Related]

  • 9. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke C E, Speller J M, Clarke J A.
    Cochrane Database Syst Rev; 2000 Aug 18; 2000(3):CD002259. PubMed ID: 10908539
    [Abstract] [Full Text] [Related]

  • 10. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R, Schechtman E, Nisipeanu P.
    Drugs Aging; 2003 Aug 18; 20(11):847-55. PubMed ID: 12964891
    [Abstract] [Full Text] [Related]

  • 11. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.
    Lancet Neurol; 2010 Jun 18; 9(6):573-80. PubMed ID: 20452823
    [Abstract] [Full Text] [Related]

  • 12. Pramipexole for levodopa-induced complications in Parkinson's disease.
    Clarke C E, Speller J M, Clarke J A.
    Cochrane Database Syst Rev; 2000 Jun 18; 2000(3):CD002261. PubMed ID: 10908540
    [Abstract] [Full Text] [Related]

  • 13. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
    Pinter MM, Rutgers AW, Hebenstreit E.
    J Neural Transm (Vienna); 2000 Jun 18; 107(11):1307-23. PubMed ID: 11145006
    [Abstract] [Full Text] [Related]

  • 14. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group.
    Clin Neuropharmacol; 2000 Jun 18; 23(1):34-44. PubMed ID: 10682229
    [Abstract] [Full Text] [Related]

  • 15. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
    Parkinson Study Group.
    JAMA; 2002 Apr 03; 287(13):1653-61. PubMed ID: 11926889
    [Abstract] [Full Text] [Related]

  • 16. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES, Factor SA, Weiner WJ, Sanchez-Ramos JR, Singer C, Shulman L, Brown D, Sheldon C.
    J Neural Transm Suppl; 1995 Apr 03; 45():225-30. PubMed ID: 8748629
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group.
    Shannon KM, Bennett JP, Friedman JH.
    Neurology; 1997 Sep 03; 49(3):724-8. PubMed ID: 9305331
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG.
    Mov Disord; 2003 Feb 03; 18(2):176-80. PubMed ID: 12539211
    [Abstract] [Full Text] [Related]

  • 20. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.
    Pogarell O, Gasser T, van Hilten JJ, Spieker S, Pollentier S, Meier D, Oertel WH.
    J Neurol Neurosurg Psychiatry; 2002 Jun 03; 72(6):713-20. PubMed ID: 12023411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.